Efficacy and Safety of Hizentra(®), a New 20% Immunoglobulin Preparation for Subcutaneous Administration, in Pediatric Patients with Primary Immunodeficiency

Subcutaneous IgG treatment for primary immunodeficiencies (PI) is particularly well suited for children because it does not require venous access and is mostly free of systemic adverse events (AEs). In a prospective, open-label, multicenter, single-arm, Phase III study, 18 children and five adolesce...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Borte, Michael, Pac, Malgorzata, Serban, Margit, Gonzalez-Quevedo, Teresa, Grimbacher, Bodo, Jolles, Stephen, Zenker, Othmar, Neufang-Hueber, Jutta, Belohradsky, Bernd
Formato: Artigo
Idioma:Inglês
Publicado em: Springer US 2011
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3221851/
https://ncbi.nlm.nih.gov/pubmed/21674136
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10875-011-9557-z
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados